TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17472817
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Simvastatin (dose ratios between 1:2 and 1:4)
Study: 15619496
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg IV/oral every 12 hours
Study: 15619496
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g IV every 12 hours
Study: 10322832
Drug: Busui Shengxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busui Shengxue Capsule (BSSXC)
Study: 10322832
Drug: Busui Shengxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busui Shengxue Capsule (BSSXC) with IL‐3, IL‐6, IL‐11
Study: 8490109
Drug: Brofaromine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Brofaromine (DB13876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine hydrochloride 75 mg after overnight fasting
Study: 8490109
Drug: Brofaromine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Brofaromine (DB13876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine hydrochloride 75 mg after a fat- and protein-rich breakfast
Study: 30748125
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium carbonate (3000 mg)
Study: 30748125
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium hydroxide/aluminum hydroxide (1600 mg each)
Study: 30748125
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium carbonate (1250 mg)
Study: 30748125
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium hydroxide/aluminum hydroxide (800 mg each)
Study: 28763003
Drug: RTD (Ready-to-Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTD (Ready-to-Drink beverage with caffeine 200 mg, β-alanine 2.1 g, arginine nitrate 1.3 g, niacin 65 mg, folic acid 325 mcg, Vitamin B12 45 mcg)
Study: 28763003
Drug: PLA (Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA (Placebo beverage with 12 g of dextrose)
Study: 21791660
Drug: AS03(A)-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H5N1 vaccine administered on different schedules (21 days, 14 days, 7 days apart, or same day)
Study: 21791660
Drug: AS03(A)-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H5N1 vaccine administered on standard schedule (21 days apart)
Study: 21791660
Drug: AS03(A)-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H5N1 vaccine administered on accelerated schedules (14 days, 7 days apart, or same day)
Study: 17108585
Drug: Computer Reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer Reminder System (CRS) for antibiotics and asthma/COPD prescriptions
Study: 17108585
Drug: Computer Reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer Reminder System (CRS) for cholesterol prescriptions
Study: 7917777
Drug: Carbamazepine therapy
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine therapy
Study: 7917777
Drug: Drug-free controls
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free controls
Study: 20048655
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene ropivacaine infusion (ropivacaine 0.2% 2 mL/hr with patient‐controlled 5‐mL boluses every hour)
Study: 20048655
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene ropivacaine infusion
Study: 18701824
Drug: Different treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatment strategies
Study: 16772285
Drug: Assisted hatching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted hatching (AH) with pronase 5 IU/ml for 1 min at 37 degrees C
Study: 12361449
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of education and mattress encasement to reduce mite allergen exposure
Study: 1096217
Drug: Cyproheptadine 4
Normalized name: cyproheptadine 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine 4 mg three times daily
Study: 23968654
Drug: Single-bolus propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-bolus propofol (2 mg/kg) based on corrected body weight (CBW60)
Study: 23968654
Drug: Single-bolus propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-bolus propofol (2 mg/kg) based on total body weight (TBW)
Study: 17764003
Drug: Intra-articular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular bupivacaine (20 ml of 0.25%)
Study: 17764003
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of 0.9% NaCl)
Study: 9735663
Drug: Anti-TP antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TP antibodies
Study: 9735663
Drug: Anti-RT antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-RT antibodies
Study: 9735663
Drug: Anti-RNase H
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-RNase H antibodies
Study: 1089426
Drug: QX-572, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: QX-572, 8 mg/kg body weight, administered as a slow intravenous infusion over 30 minutes
Study: 1089426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving saline, administered as a slow intravenous infusion over 30 minutes
Study: 30764635
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current treatment for 30 minutes, twice a day for five days postoperatively.
Study: 30764635
Drug: Sham interferential
Normalized name: thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham interferential current treatment (same pads applied without electrical stimulation).
Study: 26077006
Drug: Rheohaemapheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheohaemapheresis treatment
Study: 21694649
Drug: Nicergoline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicergoline (15 mg/d)
Study: 21694649
Drug: Imidapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5 mg/d)
Study: 19307792
Drug: Chronic steroids
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic steroids (Control)
Study: 16696632
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum plus health education (HE)
Study: 16696632
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum plus motivational interviewing (MI)
Study: 16642605
Drug: Head point-through-point
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head point-through-point electroacupuncture and oral administration of madopa
Study: 16642605
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of madopa
Study: 7554974
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vaginal gemeprost
Study: 2182615
Drug: L-tryptophan and
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan and artificial evening light
Study: 84706
Drug: CHOP regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimens (cyclophosphamide, adriamycin, vincristine, and prednisone with either low-dose bleomycin or BCG by scarification)
Study: 84706
Drug: COP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: COP regimen (cyclophosphamide, vincristine, and prednisone with low-dose bleomycin)
Study: 28722093
Drug: Wheat cellulose
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat cellulose particles (1 bag, 2 times per day) + Diosmin tablet (2 pills, 2 times per day)
Study: 28722093
Drug: Diosmin tablet
Normalized name: diosmin Oral Tablet
DrugBank: Diosmin (DB08995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin tablet (2 pills, 2 times per day)
Study: 23798635
Drug: Aggressive parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive parenteral nutrition (APN)
Study: 21563508
Drug: biomedical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: biomedical therapy (diclofenec, methotrexate, and sulfasalazine)
Study: 17121380
Drug: Inosine (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (1-2 g daily, given twice)
Study: 17121380
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment except for relapse period)
Study: 8360128
Drug: Chlorhexidine/neomycin (Naseptin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine/neomycin (Naseptin) cream
Study: 8360128
Drug: Mupirocin nasal
Normalized name: mupirocin Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin nasal ointment following failure with chlorhexidine/neomycin
Study: 3019375
Drug: Cilazapril (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (all doses)
Study: 26230741
Drug: Gabapentin 1300
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1300 mg/d
Study: 26230741
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg/d
Study: 26230741
Drug: Gabapentin 1300
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1300 mg/d and 900 mg/d
Study: 24051993
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality training using Xbox Kinect and conventional occupational therapy
Study: 19219405
Drug: SC low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC low-molecular-weight heparin (LMWH)
Study: 19219405
Drug: SC unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC unfractionated heparin (UFH)
Study: 16990410
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate for 24 months in addition to antihypertensive treatment
Study: 15548851
Drug: Lansoprazole fast
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole fast disintegrating tablet (LFDT) with 150 mL of water
Study: 15548851
Drug: Lansoprazole fast
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole fast disintegrating tablet (LFDT) without water (with saliva)
Study: 11772907
Drug: Metformin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (up to 1,000 mg twice daily)
Study: 7506223
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon-alpha 2a, administered in tapering doses thrice weekly for 1 year
Study: 24049904
Drug: Energy supplement
Normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy supplement with 200 mg of monensin added/kg of feed
Study: 24049904
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement with 200 mg of monensin added/kg of feed
Study: 24049904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (energy supplement)
Study: 24049904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (protein supplement)
Study: 31431084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of patient characteristics, trauma characteristics, and knee complaints
Study: 31431084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of patient characteristics, trauma characteristics, knee complaints, and MR findings
Study: 28607125
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid)
Study: 9646426
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g
Study: 11098023
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (PR: n = 12; PV: n = 12; PVE: n = 13)
Study: 3974174
Drug: Nimodipine (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (40, 60, or 80 mg orally)
Study: 3974174
Drug: Nimodipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (60 mg orally)
Study: 23929827
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) + manual therapy (MT)
Study: 12790293
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (220 mg) once per day for one month
Study: 10666180
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg per hour TFPI after a bolus of 0.0125 mg/kg (low-dose group)
Study: 10666180
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg per hour TFPI after a bolus of 0.05 mg/kg (high-dose group)
Study: 8877680
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine (oral formulation)
Study: 1793783
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily for one week
Study: 6571974
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium (275 mg, 2 tablets at first sign of menses, followed by one tablet 4 times daily for 3 days)
Study: 30278530
Drug: Periocular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periocular triamcinolone acetonide (TA) injection
Study: 30278530
Drug: Anti-VEGF intravitreous
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF intravitreous injection
Study: 22610930
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg/d)
Study: 22610930
Drug: Amoxicillin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1000 mg/d)
Study: 20562608
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50)
Study: 18626047
Drug: Intravenous fluconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluconazole, 800 mg daily for 2 weeks
Study: 18626047
Drug: Intravenous fluconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluconazole, 800 mg daily
Study: 11367647
Drug: Xuefuzhuyu Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuefuzhuyu Pill (XFZYP)
Study: 2462025
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field irradiation (IF) plus nitrogen mustard, vincristine, procarbazine, +/‐ prednisone (MOP[P]) chemotherapy (previous results)
Study: 21390262
Drug: Alarm (pocket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm (pocket electronic pill reminder carried for 6 months)
Study: 7883291
Drug: Zinc treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treated group (Gp B) - 45 mg elemental zinc, single daily post lunch dose
Study: 3123538
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium therapy (active)
Study: 3123538
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy (prior treatment)
Study: 25287282
Drug: Supervised resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised resistance exercise twice a week during gestational weeks 14‐25
Study: 21784350
Drug: Semagacestat (γ‐secretase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semagacestat (γ‐secretase inhibitor)
Study: 21784350
Drug: Solanezumab (anti-Aβ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanezumab (anti-Aβ monoclonal antibody)
Study: 11375848
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g IV)
Study: 7488285
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus cyclophosphamide (intravenous bolus)
Study: 7488285
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus cyclophosphamide (intravenous bolus) plus plasma exchanges
Study: 2096413
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms selenium daily for 5 weeks
Study: 31482307
Drug: L19IL2 in
Normalized name: L19IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L19IL2 in combination with dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Study: 31482307
Drug: Dacarbazine (DTIC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (DTIC; 1000 mg/m2 on day 1 of 21-day cycles)
Study: 25384996
Drug: Respiratory-gated strategy
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory-gated strategy with 4-dimensional CT treatment planning
Study: 30062746
Drug: Opioid dose
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid dose
Study: 19858764
Drug: Estrogen +
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen + progestin therapy
Study: 16262020
Drug: Metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (200 mg 3 times daily for 7 days) and cephalexin (500 mg twice daily for 5 days)
Study: 10221237
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C and 800 mg vitamin E (n = 15)
Study: 10221237
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsules (n = 16)
Study: 1702048
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glucagon (treatment group)
Study: 6342955
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tilcotil (Ro12-0068) once daily for 2 weeks
Study: 6342955
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg enteric-coated aspirin 4 times daily for 2 weeks
Study: 31710306
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Text messages (OHT)
Study: 19486267
Drug: Intralesional BCG-PSN
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional BCG-PSN injection (0.5 ml every other day for 2 weeks)
Study: 19486267
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (10 mg every week for 2 weeks)
Study: 19486267
Drug: Intralesional BCG-PSN
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional BCG-PSN injection
Study: 11606340
Drug: IM droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM droperidol 0.1 mg x kg(‐1) 30 min before anesthesia
Study: 9116924
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg titrated to 100 mg
Study: 2667265
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (ubiquinone) 3x 33.3 mg per day, orally for four months
Study: 31825192
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg)
Study: 24280596
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus ezetimibe 10 mg daily
Study: 24280596
Drug: Statin uptitration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin uptitration (double doses of statin)
Study: 22109255
Drug: varespladib methyl
Normalized name: Varespladib methyl
DrugBank: Varespladib methyl (DB05737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: varespladib methyl 500 mg daily
Study: 19445545
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (psychopharmacologic treatment combined with psychosocial interventions)
Study: 14506491
Drug: Usual nephropathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual nephropathy diet (0.8 g/kg protein, 70% animal and 30% vegetable protein)
Study: 10981570
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (160 microg in 4 ml normal saline)
Study: 10981570
Drug: Intrathecal nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nalbuphine (400 microg in 4 ml normal saline)
Study: 3709028
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral and intravenous doses of bumetanide (CRF group)
Study: 3709028
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral and intravenous doses of bumetanide (HS group)